![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Biopharmaceutics and Pharmaceutics, Showa Pharmaceutical University, Tokyo, Japan (M.K., A.M., A.T., N.A., N.K., M.F., Y.W.); Project III, National Institute of Health Sciences, Osaka Branch, Fundamental Research Laboratories for Development of Medicine, Osaka, Japan (H.M.); National Institute of Health Sciences, Tokyo, Japan (T.H.); and Department of Bacterial Toxicology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan (Y.H.)
Abstract
Claudin, a tight junction integral membrane protein and a family of proteins, forms the actual sealing element of the tight junction. There are more than 20 members of the claudin family with different tissue-specific expression and barrier functions. Thus, a family of claudin may be a target for modifying the absorption of drugs. Here, we examined whether modulation of claudin could be used to enhance drug absorption. In the current studies, we used a C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) as a modulator of claudin-4. The absorption of dextran was assessed in an in situ loop assay in rats to evaluate the absorption-enhancing effects of C-CPE. Treatment with C-CPE dose-dependently enhanced the absorption of dextran (mol. wt. 4000). These effects were not accompanied by injury of the intestinal mucosa as assessed by leakage of lactose dehydrogenase and histological observation. C-CPE was over 400-fold more potent at enhancing dextran absorption than capric acid, a clinically used enhancer of absorption. C-CPE interacted directly with claudin-4, and C-CPE lacking a part the C terminus neither bound claudin-4 nor enhanced absorption in the rat jejunum. These results suggest that C-CPE enhances the absorption of dextran in rat jejunum, apparently through interactions with claudin-4, and this effect may represent an effective novel strategy for enhancing the absorption of drugs.
Address correspondence to: Dr. Masuo Kondoh, Department of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan. E-mail: masuo{at}ac.shoyaku.ac.jp
This article has been cited by other articles:
![]() |
R. J. Mrsny, G. T. Brown, K. Gerner-Smidt, A. G. Buret, J. B. Meddings, C. Quan, M. Koval, and A. Nusrat A Key Claudin Extracellular Loop Domain is Critical for Epithelial Barrier Integrity Am. J. Pathol., April 1, 2008; 172(4): 905 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Van Itallie, L. Betts, J. G. Smedley III, B. A. McClane, and J. M. Anderson Structure of the Claudin-binding Domain of Clostridium perfringens Enterotoxin J. Biol. Chem., January 4, 2008; 283(1): 268 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Wong, D. D. Mruk, W. M. Lee, and C. Y. Cheng Targeted and reversible disruption of the blood-testis barrier by an FSH mutant-occludin peptide conjugate FASEB J, February 1, 2007; 21(2): 438 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ebihara, M. Kondoh, N. Hasuike, M. Harada, H. Mizuguchi, Y. Horiguchi, M. Fujii, and Y. Watanabe Preparation of a Claudin-Targeting Molecule Using a C-Terminal Fragment of Clostridium perfringens Enterotoxin J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 255 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Masuyama, M. Kondoh, H. Seguchi, A. Takahashi, M. Harada, M. Fujii, H. Mizuguchi, Y. Horiguchi, and Y. Watanabe Role of N-Terminal Amino Acids in the Absorption-Enhancing Effects of the C-Terminal Fragment of Clostridium perfringens Enterotoxin J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 789 - 795. [Abstract] [Full Text] [PDF] |
||||